CLINICAL_TRIALS
trial_result
· 2024-06-12
Clinical Trial Update: Bioequivalence Study of Perampanel Tablets 12 mg [Phase 1]
Summary
Phase 1 bioequivalence study evaluating 12 mg Perampanel tablets has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Epilepsy | Phase 1 | Status: COMPLETED